title: Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds.
abstract: Infections in cystic fibrosis (CF) due to Burkholderia cepacia are challenging due to their resistance to antibiotics. We explored a new strategy for increasing the permeability of B. cepacia using cationic agents, including amino compounds, to reduce the MICs of standard antibiotics. Twenty-eight B. cepacia isolates from four CF centres in North America and four non-CF B. cepacia were examined by standard microtitre broth dilution methods for susceptibility to a variety of antibiotics in the presence of non-inhibitory concentrations of diaminoacetone (DAA), methylglyoxal bis-guanylhydrazone (MGBH), chlorpromazine (CPZ) and prochlorperazine (PCPZ). The proportion of isolates with greater than four-fold reductions in MIC in the presence of 0.3 mM CPZ or 0.4 mM PCPZ were 90% and 94% for gentamicin, 80% and 83% for tobramycin, 45% and 17% for ceftazidime, and 35% and 17% for amifloxacin. CPZ showed the same degree of reduction in the MIC of azithromycin in 79% strains (MIC50 reduced to 16 from > or = 256 mg/L). Non-CF B. cepacia showed a greater than four-fold reduction in MIC with CPZ for gentamicin, tobramycin and azithromycin and two-fold reduction for ceftazidime. Little or no reduction in MIC was seen with DAA or MGBH for any antibiotic. Addition of magnesium ions to the medium competitively inhibited any MIC reduction effect seen with the cationic agents. CPZ and PCPZ appeared to enhance the permeability of B. cepacia to antibiotics based upon ionic charge characteristics of the antibiotic. No significant differences were seen in outer membrane protein and lipopolysaccharide profiles between the culture treated with CPZ and the respective control culture of strain B. cepacia ATCC 13945. The fluorescent probe 1N-phenylnaphthylamine had no increased access across the outer membrane in the presence of CPZ for B. cepacia ATCC 13945. However, thin-section electron microscopy revealed separation between the outer membrane and the rest of the cytoplasm accompanied by a widening of the periplasmic space. These data provide a rationale for investigating amino compounds as potential permeability-increasing agents against B. cepacia.
authors.affiliation: Department of Pediatric Infectious Diseases Research, Arnold Palmer Hospital for Children and Women, Orlando, FL 32806, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Rajyaguru
authors.forename: M J
authors.initials: MJ
authors.lastname: Muszynski
mesh_terms: D015057:1-Naphthylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D017963:Azithromycin / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins / Q000302:isolation & purification; D016956:Burkholderia cepacia / Q000737:chemistry / Q000187:drug effects* / Q000648:ultrastructure; D002412:Cations / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D002939:Ciprofloxacin / Q000031:analogs & derivatives / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D016576:Fleroxacin / Q000494:pharmacology; D005456:Fluorescent Dyes / Q000494:pharmacology; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology; D008274:Magnesium / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008854:Microscopy, Electron; D009675:Novobiocin / Q000494:pharmacology; D010093:Oxolinic Acid / Q000494:pharmacology; D011135:Polysaccharides, Bacterial / Q000302:isolation & purification; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000890:Anti-Infective Agents; D001425:Bacterial Outer Membrane Proteins; D002412:Cations; D005456:Fluorescent Dyes; D024841:Fluoroquinolones; D005839:Gentamicins; D011135:Polysaccharides, Bacterial; D009675:Novobiocin; D002939:Ciprofloxacin; C040691:amifloxacin; D017963:Azithromycin; C005444:N-phenyl-1-naphthylamine; D015057:1-Naphthylamine; D002442:Ceftazidime; D017291:Clarithromycin; D008274:Magnesium; D010093:Oxolinic Acid; D016576:Fleroxacin; D014031:Tobramycin